Recent studies on retatrutide, a dual agonist for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate significant findings in addressing weight gain and type 2 diabetic condition. Preliminary information from clinical experiments reveal notable decreases in body bulk and enhanced glucose levels. Further examination is directed on l